Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CCP-01
- Development stage
- Preclinical
- Lead developer
- Vernalis
- Administration
- Oral
01
Overview
CCP-01 is a prescription cough and cold medication developed for the US market. It is the first product in a series of extended-release equivalents to existing immediate-release prescription cough and cold treatments, being developed by Tris Pharma for Vernalis. The drug has completed both single-dose and multi-dose pivotal comparative bioavailability studies required to support an NDA (New Drug Application) filing. The specific active ingredients, mechanism of action, or formulation details have not been publicly disclosed as of the latest available information. Its primary indication is for use as a prescription treatment in the cough/cold therapeutic area[1][2][3].
Beyond the preview
Go deeper on CCP-01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CCP-01.